Terminated Drugs and Studies, High Costs with No Return
Developing new drugs is a difficult and costly challenge for the Life Science industry.
The cost of bringing a new drug to market is estimated somewhere between 1 and 5 billion dollars. One of the largest costs in bringing a drug to market is the clinical trial process, most studies fail as many compounds fall by the way side for various reasons, incurring heavy costs which continue to accrue after termination.
Download this white paper to learn:
- How you can achieve financial benefits by utilizing outsourcing for terminated study reporting
- Reducing Costs and Releasing Internal Resources
- Sponsor costs Conversion per study
- How to meet regulations with minimal effort and resources